Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2003; 41(1): 27-30DOI: 10.1055/s-2003-36664 Leitlinien der DGVS © Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York Akuter Schub Acute EpisodeJ. Schölmerich1 1Klinik für innere Medizin, Universitätsklinikum Regensburg Recommend Article Abstract Buy Article Full Text References Literatur 1 Stallmach A, Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel disease. Inflamm Bowel Dis. 2002; 8 213-218 (IV) 2 Colombel J F, Lémann M. et al . A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999; 94 674-678 (Ib) 3 Gerhardt H, Seifert F, Buvari P. et al . Therapie des aktiven Morbus Crohn mit dem Boswellia-serrata-Extrakt H 15. Z Gastroenterol. 2001; 39 11-17 (Ib) 4 Mahida Y R, Jewell D P. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion. 1990; 45 88-92 (Ib) 5 Modigliani R, Colombel J F, Dupas J L. et al . Mesalamine in Crohn’s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Groupe d’Études Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1996; 110 688-693 (Ib) 6 Prantera C, Cottone M, Pallone F. et al . Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999; 116 521-526 (Ib) 7 Rasmussen S N, Lauritsen K, Tage-Jensen U. et al . 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987; 22 877-883 (Ib) 8 Rijk M C, van Hogezand R A, van Lier H J. et al . Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn’s disease. A double-blind, randomized, multicenter trial. Ann Intern Med. 1991; 114 445-450 (Ib) 9 Salomon P, Kornbluth A, Aisenberg J. et al . How effective are current drugs for Crohn’s disease? A meta-analysis. J Clin Gastroenterol. 1992; 14 211-215 (Ia) 10 Scholmerich J, Jenss H, Hartmann F. et al . Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn’s disease. Can J Gastoenterol. 1990; 4 446-451 (Ib) 11 Singleton J W, Summers R W, Kern F Jr. et al . A trial of sulfasalazine as adjunctive therapy in Crohn’s disease. Gastroenterology. 1979; 77 887-897 (Ib) 12 Singleton J W, Hanauer S, Gitnick G L. et al . Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology. 1993; 104 1293-1301 (Ib) 13 Thomson O O, Cortot A, Jewell D. et al . A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998; 339 370-374 (Ib) 14 Tremaine W J, Schroeder K W, Harrison J M. et al . A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol. 1994; 19 278-282 (Ib) 15 Ursing B, Alm T, Bárány F. et al . A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II. Result. Gastroenterology. 1982; 83 550-562 (Ib) 16 Van Hees P A, Van Lier H J, Van Elteren P H. et al . Effect of sulphasalazine in patients with active Crohn’s disease: a controlled double-blind study. Gut. 1981; 22 404-409 (Ib) 17 Gross V, Andus T, Fischbach W. et al . Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn’s ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol. 1995; 33 581-584 (IIa) 18 Papi C, Luchetti R, Gili L. et al . Budesonide in the treatment of Crohn’s disease: a meta-analysis. Aliment Pharmacol Ther. 2000; 14 1419-1428 (Ia) 19 Bar-Meir S, Chowers Y, Lavy A. et al . The Israeli Budesonide Study Group. Budesonide versus prednisone in the treatment of active Crohn’s disease. Gastroenterology. 1998; 115 835-840 (Ib) 20 Caesar I, Gross V, Roth M. et al . Treatment of active and postactive ileal and colonic Crohn’s disease with oral pH-modified-release budesonide. German Budesonide Study Group. Hepatogastroenterology. 1997; 44 445-451 (IIa) 21 Campieri M, Ferguson A, Doe W. et al . Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut. 1997; 41 209-214 (Ib) 22 Greenberg G R, Feagan B G, Martin F. et al . Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994; 331 836-841 (Ib) 23 Gross V, Andus T, Caesar I. et al . Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996; 8 905-909 (Ib) 24 Rutgeerts P, Löfberg R, Malchow H. et al . A comparison of budesonide with prednisolone for active Crohn’s disease. N Eng J Med. 1994; 331 842-845 (Ib) 25 Brignola C, De Simone G, Belloli C. et al . Steroid treatment in active Crohn’s disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther. 1994; 8 465-468 (IIa) 26 Chun A, Chadi R M, Korelitz B I. et al . Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn’s disease: a randomized double-blind study and follow-up. Inflamm Bowel Dis. 1998; 177-181 (Ib) 27 Ewe K, Press A G, Singe C C. et al . Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology. 1993; 105 367-72 (Ib) 28 Heuschkel R B, Menache C C, Megerian J T. et al . Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000; 31 8-15 (Ia) 29 Landi B, Anh T N, Cortot A. et al . Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Group d’Études Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1992; 102 1647-1653 (Ib) 30 Lindor K D, Fleming C R, Burnes J U. et al . A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn’s disease. Mayo Clin Proc. 1992; 67 328-333 (IIa) 31 Lochs H, Steinhardt H J, Klaus-Wentz B. et al . Comparison of enteral nutrition and drug treatment in active Crohn’s disease. Results of the European Cooperative Crohn’s Disease Study. IV. Gastroenterology. 1991; 101 881-888 (Ib) 32 Malchow H, Ewe K, Brandes J W. et al . European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984; 86 249-266 (Ib) 33 Markowitz J, Grancher K, Kohn N. et al . A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000; 119 895-902 (Ib) 34 Summers R W, Switz D M, Sessions J T Jr. et al . National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979; 77 847-869 (Ib) 35 Pearson D C, May G R, Fick G H. et al . Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med. 1995; 123 132-142 (Ia) 36 Candy S, Wright J, Gerber M. et al . A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut. 1995; 37 674-678 (Ib) 37 Greenberg G R, Fleming C R, Jeejeebhoy K N. et al . Controlled trial of bowel rest and nutritional support in the management of Crohn’s disease. Gut. 1988; 29 1309-1315 (IIb) 38 Griffiths A M, Ohlsson A, Sherman P M. et al . Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology. 1995; 108 1056-1067 (Ia) 39 Borgaonkar M R, MacIntosh D G, Fardy J M. A meta-analysis of antimycobacterial therapy for Crohn’s disease. Am J Gastroenterol. 2000; 95 725-729 (Ia) 40 Greenbloom S L, Steinhart A H, Greenberg G R. Combination ciprofloxacin and metronidazole for active Crohn’s disease. Can J Gastroenterol. 1995; 12 53-56 (IIb) 41 Prantera C, Zannoni F, Scribano M L. et al . An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxazin. Am J Gastroenterol. 1996; 91 328-332 (Ib) 42 Sutherland L, Singleton J, Sessions J. et al . Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut. 1991; 32 1071-1075 (Ib) 43 Triantafillidis J K, Nicolakis D, Emmanoullidis A. et al . Ornidazole in the treatment of active Crohn’s disease: short-term results. Ital J Gastroenterol. 1996; 28 10-14 (IIa) 44 Targan S R, Hanauer S B, van Deventer S J. et al . A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997; 337 1029-1035 (Ib) 45 Lochs H, Adler G, Beglinger C H. et al . Anti-TNF antibody in Crohn’s disease - status of information, comments and recommendation of an international working group. Z Gastroenterol. 1999; 37 509-512 (IV) 46 Williams S E, Grundman M J, Baker R D. et al . A controlled trial of disodium cromoglycate in the treatment of Crohn’s disease. Digestion. 1980; 20 395-398 (Ib) 47 Schölmerich J. Therapeutische Innovationen bei chronisch- entzündlichen Darmerkrankungen durch „biologische Therapie” - Anti-TNF und andere. Internist. 2002; 43 1386-1399 (IV) 48 Sandborn W J, Feagan B G, Hanauer S B. et al . A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002; 122 512-530 (IV)
